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Insulin resistance is the primary cause of type 2 dia-
betes. However, if compensated by increased insulin pro-
duction, insulin resistance by itself does not lead to overt
disease. Type 2 diabetes develops when this compensation
is insufﬁcient, due to defects in ¯-cell function and in reg-
ulation of the ¯-cell mass. ¯-Cell transplantation, as well
as approaches that replenish or preserve the endogenous
¯-cellmass,mayfacilitatethetreatmentoftype2diabetes
in patients requiring exogenous insulin.
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Type 2 diabetes is a genetic disease aggravated by obesity
[1]andasedentarylifestyle.Insulinresistanceisthoughttobe
the primary metabolic abnormality in type 2 diabetes. How-
ever, if compensated by increased insulin production, insulin
resistance itself does not lead to diabetes. In obese nondia-
betic people, the pancreatic islet ¯ cells respond to insulin
resistance by increased insulin biosynthesis and secretion [2].
In addition, insulin output is regulated by expansion of the
¯-cell mass, which has been observed in both obese nondi-
abetic people [3] and rodent models of obesity. In patients
with type 2 diabetes, the compensatory effect of ¯ cells is in-
sufﬁcient. This may result both from functional impairments
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in glucose-induced insulin secretion from ¯ cells [4], as well
as abnormalities in maintenance and expansion of the ¯-cell
mass.The¯-cellmassisthenetresultofanumberofdynamic
processes, including ¯-cell replication, islet neogenesis from
pancreatic ducts, and ¯-cell death [5]. A recent analysis of
pancreatic tissue from autopsies of patients with type 2 dia-
betes documented a signiﬁcant decrease in ¯-cell mass [3].
The ﬁndings suggested that islet neogenesis was normal in
type 2 diabetes, while the rate of ¯-cell apoptosis was sig-
niﬁcantly increased, compared with nondiabetic controls [3].
Thus, instead of showing an increase in ¯-cell mass, aimed
at compensation for insulin resistance, patients with type 2
diabetes manifest a reduction in ¯-cell mass, compared with
normal subjects.
Current therapy of type 2 diabetes includes changes in diet
and exercise, as well as the use of drugs that increase insulin
secretion, reduce hepatic glucose output, and increase target
cellsensitivitytoinsulin.Eventually,administrationofexoge-
nous insulin is required to normalize blood glucose in a sig-
niﬁcant number of patients. Expansion of the ¯-cell mass by
stimulation of ¯-cell replication or neogenesis, by protection
of ¯ cells from apoptosis, as well as by ¯-cell transplantation,
may facilitate the treatment of type 2 diabetes.
REPLENISHMENT AND PRESERVATION
OF THE ENDOGENOUS ¯-CELL MASS
The emerging understanding of embryonic ¯-cell devel-
opment [6], and of ¯-cell regeneration in the adult pancreas
frompancreaticducts[7],mayholdthepromiseofdeveloping
approaches to stimulate endogenous ¯-cell replenishment by
neogenesis or replication. These approaches are likely to in-
volvethelocaldeliveryofgrowthfactorsorotherextracellular
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mitogenic agents, as well as the transfer of genes into pan-
creatic duct or islet cells that can modulate their replication
and differentiation, or increase their resistance to apoptosis.
Although these prospects await the development of safe and
efﬁcient methods for local delivery of proteins and genes, it is
possiblethatsystemictreatmentwithgrowthfactorsmaylead
to a signiﬁcant expansion of the ¯-cell mass without deleteri-
ous effects to other tissues. One example for such a factor is
exendin-4,astableanalogofglucagon-likepeptide1(GLP1),
whichhasbeenshowntostimulateboth¯-cellneogenesisand
replication in a rat model of type 2 diabetes involving partial
pancreatectomy [8]. In a recent work using Goto-Kakizaki
rats, a nonobese model of type 2 diabetes, injections of GLP1
or exendin-4 increased the ¯-cell mass, resulting in long-term
improvements in glycemia [9]. GLP-1 is a particularly attrac-
tive candidate because of its additional stimulatory effects on
glucose-induced insulin secretion from ¯ cells [10]. Numer-
ousotherhormonesandgrowthfactorsareknowntostimulate
duct cell differentiation into islets and ¯-cell replication (see
[11] for a recent review); however, most of them are unlikely
to be suitable for systemic treatment due to pleotropic effects
in other tissues.
¯-CELL TRANSPLANTATION
The alternative to stimulating the replenishment of the en-
dogenous ¯-cell mass is increasing it from an exogenous
source, by transplantation of alloegneic ¯ cells. The chal-
lenges facing ¯-cell transplantation in type 2 diabetes are less
daunting, compared with type 1 diabetes. Although ¯ cells
transplantedintopatientswithtype2diabetesmaybeexposed
toanenvironmentthatcouldimpairtheirfunctionorviability,
thesefactorsaremuchlesspotentandslowertoact,compared
with recurring autoimmunity facing ¯-cell transplantation in
type 1 diabetes. In addition, the effect of these factors may
decrease with improvement in glycemia. Similarly, although
regulated insulin secretion is a critical requirement from cells
considered for transplantation into patients with type 1 dia-
betes,thisisnotaconsiderationintype2diabetes,wherelarge
amounts of insulin are needed to overcome insulin resistance.
Allogeneic ¯-cell transplantation on a large scale cannot
relyonscarcehumanisletdonorstoprovidecellsforthelarge
population of patients with type 2 diabetes who may beneﬁt
from transplantation. It will require the development of new
and abundant sources of ¯ cells, based on efﬁcient ways for
expansion of ¯ cells in tissue culture. This expansion of the
cell mass should be achieved without a loss of the ¯-cell phe-
notype, as characterized by the amounts of insulin produced
and stored in the cells, and its regulated secretion. Two differ-
ent approaches have been taken in recent years toward ¯-cell
expansion in tissue culture: (1) stimulation of replication of
mature ¯ cells and (2) induction of differentiation of progeni-
torcellsfromvarioussourcesintocellswith¯-cellproperties.
¯-Cell Expansion by Reversible
Immortalization
Because mature ¯ cells do not divide much in vitro, onco-
geneexpressionhasbeenusedtoforcetheirreplication.Stud-
ies involving expression of oncogenes in ¯ cells of transgenic
miceresultedinthedevelopmentof¯-celllines,whichproved
valuableforinvestigating¯-cellfunctionandgeneexpression
[12]. However, induction of forced replication of postmitotic
¯ cells ultimately lead to impaired insulin production and se-
cretion in these cell lines. The phenotypic instability, as well
as the uncontrolled growth, made this approach incompatible
with a therapeutic application.
These shortcomings were overcome by the development
of conditional gene expression systems, which allowed re-
versible regulation of oncogene expression. Expression of
SV40largeTantigen(Tag)oncoproteinin¯ cellsintransgenic
miceundercontrolofthetet-offandtet-onsystemsresultedin
the generation of differentiated ¯-cell lines with a stable phe-
notype[13–15].Suchcellscouldbeexpandedintissueculture
by oncogene expression, and induced to undergo growth ar-
rest in its absence, using tetracycline (tet) ligands. Following
growth arrest, the cells increased their insulin storage sever-
alfold, up to the levels typical of normal mouse islets, and
maintained normal regulation of insulin secretion in response
to glucose in the physiological concentration range [14, 15].
When transplanted into streptozotocin-induced diabetic syn-
geneic mice, these cells restored euglycemia and maintained
it for long periods of time [13, 15]. Using the tet-on approach
had the advantage of avoiding the need to treat transplanted
animals with tet ligands following transplantation to prevent
oncogene expression and undesired cell expansion.
Unfortunately, application of reversible immortalization
strategies to human ¯ cells proved to be difﬁcult. Immortal-
ized human ¯ cells tend to lose differentiation much faster
than mouse ¯ cells. Strategies for restoring the function of
dedifferentiated human ¯ cells, for example by expression
of insulin gene transcription factors, resulted in a partial
recovery of insulin production [16]; however, the phenotypic
stability of such cells in tissue culture or following transplan-
tation has not been determined. Despite effective methods for
oncogenesilencingorremoval,concernshavebeenexpressed
about the oncogenic potential of such cells. Additional safety
elements, such as using physical barriers in the form of
semipermeable membrane devices, or cell engineering with
suicide genes to allow cell elimination in case of device
failure, will be needed to address these concerns.¯-CELL EXPANSION FOR TREATMENT OF TYPE 2 DIABETES 3
Development of Insulin-Producing Cells
From Embryonic or Tissue Stem Cells
The alternative to expansion of mature ¯ cells is differ-
entiation of stem or progenitor cells into surrogate ¯ cells.
Stem cells possess a natural replication capacity in tissue
culture. When allowed to spontaneously differentiate, both
murine and human embryonic stem (ES) cells give rise to
a low percentage of insulin-producing cells [17, 18]. Initial
efforts were directed toward isolation of these relatively rare
cellsusingselectionprocedures.Subsequently,protocolswere
developed to increase the fraction of ES cells that develop
into insulin-producing cells. McKay and coworkers selected
nestin-positive neuroendocrine precursor cells, which devel-
oped from mouse ES cells, and utilized combinations of sol-
uble factors to promote their differentiation in tissue culture
into islet cell types [19]. Hori and colleagues treated mouse
EScellswithinhibitorsofphosphoinositide3-kinase,thereby
generating cells that produced signiﬁcant insulin levels and
released it in response to glucose [20]. Although insulin-
producing cells developed from ES cells were able to normal-
ize glycemia in mice, the ability of such cells derived from
humanEScellstoreplacethefunctionofdifferentiated¯ cells
in humans remains unknown.
Inadditiontostemcellsderivedfromearly-stageembryos,
evidencesuggeststhatmanyfetalandadulttissuescontainim-
mature cells, which are responsible for tissue renewal. Such
cells maintain a replicative capacity and an ability to differ-
entiate into a number of cell types. The most obvious place
to look for cells that can potentially differentiate into insulin-
producing cells is the pancreas. Duct cells can form islet-like
structures in culture [21, 22]; however, they are difﬁcult to
expand. The isolation and characterization of the pancreatic
islet stem cells remains a goal for future efforts.
In recent years, the cell commitment dogma has been chal-
lenged by reports that progenitor cells from adult organs can
give rise to unrelated cell types, both in vivo and in culture.
It is unclear at present whether these ﬁndings represent bona
ﬁde “transdifferentiation,” or the persistence of residual em-
bryonic pluripotent cells in adult tissues. The most striking
example is bone marrow cells from both mice and humans,
which were shown to give rise to a diverse range of cell types
from other tissues [23]. Although the natural plasticity of tis-
suestemcellsisstillbeingdebated,thereisevidencethatpro-
genitorcellscommittedtodevelopintocertaintissuescanbeat
leastpartlyreprogrammedwithdominantgenesthatactivatea
cascade of developmental events. For example, expression of
a homeobox transcription factor, Pdx1, which plays key roles
in pancreas development and gene expression in mature ¯
cells, in mouse liver cells in vivo [24], and in rat enterocytes
in vitro [25], was shown to activate ¯-cell genes, including
insulin. Liver progenitor cells represent an attractive source,
because liver and pancreas share embryological origin from
the primitive foregut. In addition, mature hepatocytes and ¯
cells manifest similarities in gene expression proﬁles, such
as transcription factors, the glucose transporter GLUT2, and
the glucose-phosphorylating enzyme glucokinase. Progeni-
tor cells cultured from mouse fetal liver were shown to be
pluripotent and differentiate in vivo into a number of hepatic,
pancreatic, and intestinal cell types [26]. Furthermore, adult
rat hepatic stem cells, termed oval cells, were shown to dif-
ferentiate into pancreatic endocrine cells in vitro [27]. New
insightsintothecascadeoftranscriptionfactorsthatactduring
endocrine pancreas development [6] will allow the employ-
ment of combinations of such factors in an effort to direct the
differentiation of liver and other tissue stem cells into ¯-like
cells.
CONCLUDING REMARKS
Increasing the ¯-cell mass is likely to improve glycemia
and replace insulin administration in patients with type 2 di-
abetes. Although progress has been made in our understand-
ing of genes involved in ¯-cell development and factors that
regulate ¯-cell differentiation, replication, and survival, ap-
proaches for replenishment or preservation of endogenous ¯
cells in humans are not available at present. In contrast, trans-
planted¯ cells,whichcanbegeneticallymanipulatedintissue
culturetoimprovetheirfunctionandsurvival,mayrepresenta
more realistic approach. Recent progress in ¯-cell expansion
in tissue culture and the formation of insulin-producing cells
from stem and progenitor cells holds the promise of develop-
ing abundant cell sources for transplantation. Another impor-
tant consideration, beyond technical feasibility, is the func-
tional performance of endogenous versus transplanted cells.
Itisnotknownwhetherthefunctionalabnormalitiesobserved
in ¯ cells in type 2 diabetes, as well as the increased rate of
apoptosis, are caused by genetic defects or by epigenetic fac-
tors, such as the chronic hyperglycemia and deposits of islet
amyloid polypeptide (IAPP), which characterize the ¯-cell
milieuintype2diabetes.Althoughtheeffectsofthesefactors
may take a long time to manifest themselves, in both cases
¯-cell transplantation may be more advantageous, compared
with replenishment or preservation of endogenous ¯ cells. If
epigenetic conditions are the main cause of ¯-cell failure in
type 2 diabetes, autologous and allogeneic new ¯ cells will
be equally susceptible to a gradual deterioration in their func-
tion and viability. However, genetic engineering of the trans-
planted cells with genes involved in insulin production and
secretion, as well as antiapoptotic genes, may prolong their
normal function and survival following transplantation. Such4 S. EFRAT
genetic manipulations are much harder to perform in cells
formed endogenously, due to the difﬁculty of targeting viral
vectors to the pancreas. In the event that intrinsic ¯-cell ab-
normalities originating from genetic defects are the primary
cause of impaired ¯-cell function and increased apoptosis in
type 2 diabetes, new ¯ cells formed endogenously may de-
teriorate faster, compared with transplanted allogeneic cells.
Thus,whencellfunctionaloneisconsidered,itmaybeprefer-
able to increase the ¯-cell mass using an exogenous, rather
than an endogenous, source of ¯ cells. On the other hand,
the risks of immunosuppression, as well as the challenges
of achieving appropriate vascularization and regulation of ¯
cells placed outside the pancreas, are considerations against
cell transplantation. Moreover, before proceeding with any
therapy for type 2 diabetes that is based on cell manipulation,
its risks will have to be weighed against the improvement in
glycemia, in comparison with that achieved with simple in-
sulin administration.
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